Asymptomatic Cardiotoxicity After High‐Dose Anthracycline Treatment in Sarcoma Patients Assessed by Biomarkers and Echocardiography
International Journal of Cancer · 2026
DOI: 10.1002/ijc.70620 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Elissa A S Polomski und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Heart Lung Center, Leiden University Medical Center, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Anthracyclines, Sarcoma, Cardiotoxicity. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Treatment of sarcoma includes high‐dose anthracyclines, which can cause cardiotoxicity. This study assesses the correlation of cardiac biomarkers and echocardiographic parameters on asymptomatic cardiotoxicity in sarcoma patients treated with anthracyclines. Consecutive patients diagnosed with sarcoma and treated with anthracyclines were included in this retrospective cohort study using registry data. Echocardiography was performed before start of anthracycline chemotherapy (baseline), after completing treatment (short‐term follow‐up), and 6–12 months after termination of treatment (long‐term follow‐up). The primary endpoint was the occurrence of asymptomatic cardiotoxicity at short‐term follow‐up. We included 44 patients (29.6% female) with a median age of 28.9 [22.2–38.7] years. Baseline left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS) decreased significantly from 58.4% ± 5.0% to 54.2% ± 9.3% ( p = 0.013) and −19.1% ± 2.2% to −17.2% ± 3.5% at short‐term follow‐up ( p = 0.002), respectively. After Cycle 1, 86.5% of the patients showed NT‐proBNP ≥ 125 ng/L compared to 3.9% at baseline ( p < 0.001), and after completion of therapy, 65.5% had elevated cardiac Troponin T (cTnT) ≥ 14 ng/L compared to 11.5% at baseline ( p = 0.003). Asymptomatic cardiotoxicity was observed in 30 patients (68.2%). Mean follow‐up was 2.4 [1.5–2.9] years. cTnT ≥ 14 ng/L after Cycle 4 was associated with cardiotoxicity (HR: 3.75 [1.28–11.0], p = 0.016), and NT‐proBNP per 100 units increase after Cycle 1 was associated with an increased risk of mortality (HR: 1.36 [1.004–1.85], p = 0.047). Sarcoma patients treated with high‐dose anthracyclines are at increased risk of developing cardiac dysfunction as assessed by LVEF and GLS. cTnT and NT‐proBNP levels increase significantly during treatment and can be valuable markers to improve the risk stratification of patients treated with high‐dose anthracyclines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Heart Lung Center, Leiden University Medical Center, Leiden, the Netherlands.
- Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.
- Netherlands Heart Institute, Utrecht, the Netherlands.
- Department of Orthopedic Surgery, Leiden University Medical Center, Leiden, the Netherlands.
ORCID-Profile: Elissa A S Polomski
Zitieren
APA
Polomski, E. A. S., Speetjens, F. M., Jukema, J. W., Heemelaar, J. C., van de Sande, M. A. J., Gelderblom, H., & Antoni, M. L. (2026). Asymptomatic Cardiotoxicity After High‐Dose Anthracycline Treatment in Sarcoma Patients Assessed by Biomarkers and Echocardiography. International Journal of Cancer. https://doi.org/10.1002/ijc.70620
Vancouver
Polomski EAS, Speetjens FM, Jukema JW, Heemelaar JC, van de Sande MAJ, Gelderblom H, et al. Asymptomatic Cardiotoxicity After High‐Dose Anthracycline Treatment in Sarcoma Patients Assessed by Biomarkers and Echocardiography. International Journal of Cancer. 2026. doi:10.1002/ijc.70620
BibTeX
@article{Polomski2026,
author = {Polomski, Elissa A S and Speetjens, Frank M and Jukema, J Wouter and Heemelaar, Julius C and van de Sande, Michiel A J and Gelderblom, Hans and Antoni, M Louisa},
title = {Asymptomatic Cardiotoxicity After High‐Dose Anthracycline Treatment in Sarcoma Patients Assessed by Biomarkers and Echocardiography},
journal = {International Journal of Cancer},
year = {2026},
doi = {10.1002/ijc.70620}
}
EUVIMED